Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21709222 | 1.00 | NUDT1 (0.44) | NUDT1MEN1KMT2AGAAMAPT | |
| SCHEMBL21709373 | 0.89 | NUDT1 (0.42) | NUDT1MEN1KMT2AGAAMAPT | |
| SCHEMBL21709220 | 0.89 | NUDT1 (0.46) | NUDT1MEN1KMT2AGAAMAPT | |
| SCHEMBL21709503 | 0.88 | MEN1 (0.47) | NUDT1MEN1KMT2AGAAMAPT | |
| SCHEMBL21709382 | 0.88 | MEN1 (0.47) | NUDT1MEN1KMT2AGAAMAPT | |
| SCHEMBL21709223 | 0.87 | NUDT1 (0.41) | NUDT1MEN1KMT2AGAAMAPT | |
| SCHEMBL21709379 | 0.84 | MEN1 (0.45) | NUDT1MEN1KMT2AGAAMAPT | |
| SCHEMBL21709371 | 0.83 | NUDT1 (0.45) | NUDT1MEN1KMT2AGAAMAPT | |
| SCHEMBL21709506 | 0.82 | NUDT1 (0.40) | NUDT1MEN1KMT2AGAAMAPT | |
| SCHEMBL15213633 | 0.80 | PDK2 (0.36) | MEN1KMT2AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048207-A1 | COMPOUNDS WITH ARYLAMINE STRUCTURES | MERCK PATENT GMBH (DE) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048207-A1 | COMPOUNDS WITH ARYLAMINE STRUCTURES | DDT, NAT1, INMT | NUDT1 15/4885MEN1 2014/4885KMT2A 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.